Biocompatibility of sulphonated polyurethane surfaces

Biomaterials

Volumn 17, Issue 20, 1996, Pages 1987-1994

  Keogh, James R ^a   Wolf, Mike F ^a   Overend, Mary E ^a   Tang, Liping ^b   Eaton, John W ^b  

^a MEDTRONIC INC   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Biocompatibility; Heparin; Inflammation; Polyurethanes; Thrombosis

Indexed keywords

ACRYLIC MONOMERS; BIOCOMPATIBILITY; BLOOD; CATHETERS; COAGULATION; COPOLYMERIZATION; DERIVATIVES; FREE RADICAL POLYMERIZATION; FREE RADICALS; IMPLANTS (SURGICAL); PHYSIOLOGICAL MODELS; SURFACES;

ADHERENT SLEEVE THROMBI; BIOMATERIAL MEDIATED THROMBOSIS; CENTRAL VENOUS CATHETERS; HEPARIN; INFLAMMATION; NONANTICOAGULATED CANINE FEMORAL VEINS; NONANTICOAGULATED HUMAN BLOOD; SURFACE DERIVATIZATION;

POLYURETHANES;

BETA THROMBOGLOBULIN; BIOMATERIAL; COMPLEMENT COMPONENT C3A; FIBRINOPEPTIDE A; POLYURETHAN; SULFONIC ACID DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTICOAGULATION; ARTICLE; BIOCOMPATIBILITY; BLOOD; CENTRAL VENOUS CATHETER; DOG; FEMALE; FEMORAL VEIN; HUMAN; HUMAN CELL; IMPLANT; INFLAMMATION; NEUTROPHIL; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; THROMBOCYTE ADHESION; THROMBOSIS;

EID: 0030272710     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/0142-9612(96)00005-1     Document Type: Article

References (72)

1. 1 Lindsay R. Blood surface interactions. Trans Am Soc Artif Int Organs 1980; 26: 603-610.
2. 2 Leininger R, Hutson T, Jackobsen R. Spectroscopic approaches to the investigation of interactions between artificial surfaces and proteins. Ann NY Acad Sci 1987; 516: 173-183.
3. 3 Zucker MB, Vroman L. Platelet adhesion induced by fibrinogen adsorbed onto glass. Proc Soc Exp Biol Med 1969; 131: 318-320.
4. 4 Kim SW, Lee ES. The role of adsorbed proteins in platelet adhesion onto polymer surfaces. J Polym Sci, Polym Symp 1979; 66: 429-441.
5. 5 Horbett T. Protein adsorption on biomaterials. In: Cooper SL, Peppas NA, eds. Biomaterials: Interfacial Phenomena and Applications. Advances in Chemistry Series, Vol. 199. American Chemical Society, 1982: 233-244.
6. 6 Absolom D, Zingg W, Neumann A. Protein adsorption to polymer particles: role of surface properties. J Biomed Mater Res 1987; 21: 161-171.
7. 7 Collins W, Mosher D, Tomasini B, Cooper SA. Preliminary comparison of the thrombogenic activity of vitronectin and other RGD-containing proteins when bound to surfaces. Ann NY Acad Sci 1987; 516: 291-299.
8. 8 Salzman E, Lindon J, McManama G, Ware J. Role of fibrinogen in activation of platelets by artificial surfaces. Ann NY Acad Sci 1987; 516: 184-195.
9. 9 Ito Y, Iguchi Y, Kashiwagi T, Imanishi, Y. Synthesis and nonthrombogenicity of polyurethaneurea film grafted with poly(sodium vinyl sulfonate). J Biomed Mater Res 1991; 25: 1347-1361.
10. 10 Fukumura H, Hayashi K, Yoshikawa S, Miya M, Yamamoto N, Yamashita I. Complement-induced thrombus formation on the surface of poly(N-vinylpyrrolidone)-grafted polyethylene. Biomaterials 1987; 8: 74-76.
11. 11 Tang L, Eaton JW. Fibrin(ogen) mediates acute inflammatory responses to biomaterials. J Exp Med 1993; 178: 2147-2156.
12. 12 Bick RL. Hypercoagulability and thrombosis. Common Bleeding and Clotting Disorders 1994; 78: 635-665.
13. 13 Pixley RA, Schapira M, Colman RW. Effect of heparin on the inactivation rate of human activated factor XII by antithrombin III. Blood 1985; 66: 198-203.
14. 14 Bjork I, Lindahl U. Mechanism of the anticoagulant action of heparin. Mol Cell Biochem 1982; 48: 161-182.
15. 15 Tanzi MC, Barozzi C, Tieghi G, Ferrara R, Casini G, Tempesti F. Heparinizable graft copolymers from chlorosulphonated polyethylene with poly(amidoamine) segments. Biomaterials 1985; 6: 273-276.
16. 16 Noishiki Y, Miyata T. A simple method to heparinize biological materials. J Biomed Mater Res 1986; 20: 337-346.
17. 17 Barbucci R, Baszkin A, Benvenuti M, Costa M, Ferruti P. Surface characterization of heparin-complexing poly(amido amine) chains grafted on polyurethane and glass surfaces. J Biomed Mater Res 1987; 21: 443-457.
18. 18 Eloy R, Belleville J, Rissoan MC, Baguet J. Heparinization of medical grade polyurethanes. J Biomater Appl 1988; 2: 475-518.
19. 19 Barbucci R, Magnani A, Albanese A, Tempesti F. Heparinized polyurethane surface through ionic bonding of heparin. Int J Artif Organs 1991; 14: 499-507.
20. 20 Silver JH, Hart AP, Williams EC, Cooper SL, Charef S, Labarre D, Jozefowicz M. Anticoagulant effects of sulphonated polyurethanes. Biomaterials 1992; 13: 339-344.
21. 21 Larm O, Larsson R, Olsson P. A new non-thrombogenic surface prepared by selective covalent binding of heparin via modified reducing terminal residue. Biomater Med Dev, Art Org 1983; 11: 161-173.
22. 22 Lindon JN, Salzman EW, Merrill ED, Dincer AK, Labarre D, Bauer KA, Rosenberg RR. Catalytic activity and platelet reactivity of heparin covalently bonded to surfaces. J Lab Clin Med 1985; 105; 219-226.
23. 23 Arnander C. Enhanced patency of small-diameter tubings after surface immobilization of heparin fragments. A study in the dog. J Biomed Mater Res 1989; 23: 285-294.
24. 24 Park KD, Kim WG, Jacobs H, Okano T, Kim SW. Blood compatibility of SPUU-PEO-heparin graft copolymers. J Biomed Mater Res 1991; 26: 739-756.
25. 25 Linhardt RJ, Galliher PM, Cooney CL. Polysaccharide lyases. Appl Biochem Biotech 1986; 12; 135-176.
26. 26 Kanmangne FM, Labarre D, Serne H, Jozefowicz M. Heparin-like activity of insoluble sulphonated polystyrene resins. Biomaterials 1985; 6: 297-302.
27. 27 Migonney V, Fougnot C, Jozefowicz M. Heparin-like tubings. Biomaterials 1988; 9: 413-418.
28. 28 Grasel TG, Cooper SL. Properties and biological interactions of polyurethane anionomes: Effect of sulfonate incorporation. J Biomed Mater Res 1989; 23: 311-338.
29. 29 Han DK, Ryu GH, Park KD, Jeong SY, Kim YH, Min BG. Adsorption of plasma proteins on sulfonated poly(ethyleneoxide)-grafted polyurethane. Soc Biomater Trans 1994; 292.
30. 30 Linhardt RJ, Rice KG, Kim YS, Engelken JD, Weiler JM. Homogeneous, structurally defined heparin-oligosaccharides with low anticoagulant activity inhibit the generation of the amplification pathway C3 convertase in vitro. J Biol Chem 1988; 263: 13090-13096.
31. 31 Hasdai D, Blumberg N, Battler A. The non-antithrombotic therapeutic potential of heparin and related heparinoids in cardiovascular diseases. Coronary Artery Disease 1994; 5: 81-91.
32. 32 Weiler JM, Edens RE, Linhardt RJ, Kapelanski DP. Heparin and modified heparin inhibit complement activation in vivo. J Immunol 1992; 148: 3210-3215.
33. 33 Pasini FL, Pasquoi AL, Ceccatelli L, Capecchi PL, Orrico A, Di Perri T. Heparin inhibition of polymorphonuclear leukocyte activation in vitro. A possible pharmacological approach to granulocyte-mediated vascular damage. Thromb Res 1984; 35: 527-537.
34. 34 Brestel EP, McClain EJ. A mechanism for inhibition of luminol-dependent neutrophil chemiluminescence by polyanions. J Immunol 1983; 131: 2515-2519.
35. 35 Redini F, Tixier JM, Petitou M, Choay J, Robert L, Hornebeck W. Inhibition of leukocyte elastase by heparin and its derivatives. Biochem J 1988; 252: 515-519.
36. 36 Marossy K. Interaction of the chymotrypsin and elastase-like enzymes of the human granulocyte with glycosaminoglycans. Biochem Biophys Acta 1981; 659: 351-361.
37. 37 Hocking DC, Ferro TJ, Johnson A. Dextran sulfate inhibits PMN-dependent pulmonary edema induced by tumor necrosis factor. J Appl Physiol 1991; 70: 1121-1128.
38. 38 Holmer E, Lindahl U, Backstrom G, Thunberg L, Sandberg H, Soderstrom G, Andersson L. Anticoagulant activities and effects on platelets of a heparin fragment with high affinity for antithrombin. Thromb Res 1980; 18: 861-869.
39. 39 Engelberg H. Heparin and the atherosclerotic process. Pharmacol Rev 1984; 36: 91-109.
40. 40 Gallagher JT, Walker A. Molecular distinctions between heparan sulphate and heparin. Biochem J 1985; 230: 665-674.
41. 41 Sarath MD, Merchant ZM, Kim YS, Rice KG, Linhardt RJ, Weiler JM. Small heparin fragments regulate the amplification pathway of complement. Immunopharmacology 1985; 9: 73-80.
42. 42 Kazatchkine MD, Fearon DT, Metcalfe DD, Rosenberg RD, Austen KF. Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase. J Clin Invest 1981; 67: 223-228.
43. 43 Feng X, Sun Y, Qiu K. Reaction site and mechanism of graft copolymerization onto poly(ether urethane) with ceric ion initiator. Macromolecules 1985; 18: 2105-2109.
44. 44 Herzlinger GA, Cumming RD. Role of complement activation in cell adhesion to polymer blood contact surfaces. Trans Am Soc Artif Int Organs 1980; 26: 165-171.
45. 45 Fukumura H, Hayashi K, Yoshikawa S, Miya M, Yamamoto N, Yamashita I. Complement-induced thrombus formation on the surface of poly[N-vinylpyrrolidone)-grafted polyethylene. Biomaterials 1987; 8: 74-76.
46. 46 Roitt I, Brostoff J, Male D. Immunology. Grower Medical Publishing Ltd., 1987.
47. 47 Wolf MF, Trescony PV, Keogh JR. Apparatus for testing blood-biomaterial/device interactions and characteristics. United States Patent No. 5,271,898, 1993.
48. 48 Haycox CL, Ratner BD. In-vitro platelet interactions in whole blood exposed to biomaterial surfaces: Insights on blood compatibility. J Biomed Mater Res 1993; 27: 1181-1193.
49. 49 Wolf MF, Coscio MR, Bianco RW. Comparison of luminal surface observations of the wound healing response of an experimental small diameter woven dacron and expanded polytetrafluoroethylene arterial prosthesis. 49th Annual Meeting of the Electron Microscopy Society of America, August 1991.
50. 50 Wolf MF, Coscio MR, Cheevers L, Irwin E. Morphological features of cardiovascular implants preserved using simple in situ perfusion fixation techniques. Implant Retrieval Symposium, Society for Biomaterials, September 1992.
51. 51 Brown DL. Annotation: Complement and coagulation. Br J Hæmatol 1975; 30: 377-382.
52. 52 Marchant RE. Cell adhesion and interactions with biomaterials. J Adhesion 1986; 20: 211-225.
53. 53 Gemmell CH, Yeo EL, Sefton MV. The role of complement in leukocyte and platelet activation as assessed by flow cytometry. Soc Biomater Trans 1994; 73.
54. 54 Keogh JR, Eaton JW. Albumin binding surfaces for biomaterials. J Lab Clin Med 1994; 124: 537-545.
55. 55 Packman MA, Mustard JF. Clinical pharmacology of platelets. Blood 1977; 50: 555-573.
56. 56 Sonne O. The specific binding of thrombin to human polymorphonuclear leukocytes. Scand J Clin Lab Invest 1988; 48: 831-838.
57. 57 Bizios R, Lai L, Fenton JW II, Malik AB. Thrombin-induced chemotaxis and aggregation of neutrophils. J Cell Physiol 1986; 128: 485-490.
58. 58 Weiler JH, Linhardt RJ. Comparison of the activity of polyanions and polycations on the classical and alternative pathways of complement. Immunopharmacology 1989; 17: 65-72.
59. 59 Kirklin JK, Westaby S, Blackstone EH, Kirklin JW, Chenoweth DE, Pacifico AD. Complement and the damaging effects of cardiopulmonary bypass. J Thoracic Cardiovasc Surg 1983; 86: 845-857.
60. 60 Chenoweth DE, Cooper SW, Hugli TE, Stewart RW, Blackstone EH, Kirklin JW. Complement activation during cardiopulmonary bypass. New Eng J Med 1981; 304: 497-503.
61. 61 Moore FD, Warner KG, Assoua S, Valeri CR, Khuri SF. The effects of complement activation during cardiopulmonary bypass. Ann Surg 1988; 95-103.
62. 62 Nilsson L, Storm KE, Thelin S, Bagge L, Hultman J, Thorelius J, Nilsson U. Heparin-coated equipment reduces complement activation during cardiopulmonary bypass in the pig. Artif Org 1990; 14: 46-48.
63. 63 Ito Y, Liu L, Imanishi Y. Interaction of poly(sodium vinyl sulfonate) and its surface graft with antithrombin III. J Biomed Mater Res 1991; 25: 99-115.
64. 64 Machovich R, Nagy M, Gyorgyi-Edelenyi J, Csomor K, Horvath I. Anticoagulant effect of sulphated poly/vinyl alcohol-acrylic acid/copolymers. Thromb Hæmost 1986; 56: 397-400.
65. 65 Han DK, Ryu GH, Park KD, Jeong SY, Kim YH, Min BG. Adsorption behavior of fibrinogen to sulfonated polyethyleneoxide-grafted polyurethane surfaces. J Biomater Sci Polym Ed 1993; 4: 401-413.
66. 66 Okkema AZ, Visser SA, Cooper SL. Physical and blood-contacting properties of polyurethanes based on a sulfonic acid-containing diol chain extender. J Biomed Mater Res 1991; 25: 1371-1395.
67. 67 Silver JH, Lin HB, Cooper SL. Effect of protein adsorption on the blood-contacting response of sulphonated polyurethanes. Biomaterials 1993; 14: 834-844.
68. 68 Santerre JP, ten Hove P, VanderKamp NH, Brash JL. Effect of sulfonation of segmented polyurethanes on the transient adsorption of fibrinogen from plasma: Possible correlation with anticoagulant behavior. J Biomed Mater Res 1992; 26: 39-57.
69. 69 Shibuya Y, Semba U, Okabe H, Kambara T, Yamamoto T. Primary structure of bovine Hageman factor (blood coagulation factor XII): comparison with human and guinea pig molecules. Biochim Biophys Acta 1994; 1206: 63-70.
70. 70 Karges HE, Funk KA, Ronneberger H. Activity of coagulation and fibrinolysis parameters in animals. Drug Res 1944; 44: 793-797.
71. 71 Mason RG, Read MS. Some species differences in fibrinolysis and blood coagulation. J Biomed Mater Res 1971; 5: 121-128.
72. 72 Dewanjee MK, Kapadvanjwala M, Sanchez A, Elson R, Serafini AN, Zilleruelo GE, Sfakianakif GN. Quantitation of comparative thrombogenicity of dog, pig and human platelets in a hemodialyzer. Am Soc Artif Int Org 1992; 38: 88-90.